Dimerix is a clinical-stage biopharmaceutical company, with multiple Phase 3 opportunities, developing innovative new therapies in areas with unmet medical needs.

Dimerix encourages collaboration and is well positioned to discuss partnering and product development.


Dimerix uses innovative Receptor-HIT technology to study receptor heteromers and uncover pharmaceutical products that will improve patients' lives.

Find out more

Product Pipeline

Dimerix develops new therapies through the clinic to commercialization. Our lead products are DMX-200 for FSGS and DMX-200 for COVID respiratory complications.

Find out more